Use of orthodeoxia by pulse oximetry in the detection of Hepatopulmonary Syndrome.
Main Article Content
Abstract
Chronic Hepatic deficiency due to the ingestion of alcohol remains as one of the main causes of morbidity and mortality in our country. From it a variety of complications arise, one of them is the Hepatopulmonary Syndrome, which usually goes unnoticed and undiagnosed; this syndrome is distinguished by the presence of hypoxemia and pulmonary vasodilation. The gold standard to establish a diagnostic is contrasted Echocardiogram. No pathognomonic sign is known for this syndrome, which leads the present elaboration to evaluate the use of orthodeoxia by pulse oximetry as a screening test in the detection of Hepatopulmonary Syndrome cases.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Nacif LS, Andraus W, Pinheiro RS, Ducatti L, Haddad LBP, D'Albuquerque LC. The hepatopulmonary syndrome. Arq Bras Cir Dig 2014; 27 (2): 145-147.
3. Muñoz-Jackson G. Síndrome hepatopulmonar. Rev Med Cos CEN 2014; (612) 395-401.
4. Raevens S, Geerts A, Van Satenkiste C, Verhelest X, Van Vlerberghe H, Golle I. Hepatopulmonary syndrome and portopulmonary hipertensión: reventar knowtedege in pathogenesis and overview of clinical assessment. Liver Int 2015; 35, 1646-1660.
5. Sáenz-Gómez J, Karam- Bechara J, Jamaica-Banderas L. Síndrome hepatopulmonar como causa de hipoxemia en niños con enfermedad hepática. Bol Med Hospital Infantil Mex 2015; 72(2): 124-128.
6. Muñoz-Maya OG, Santos OM, Granda P, Vega J, Martin JI, Restrepo- Gutiérrez JC. Síndrome hepatopulmonar en paciente con hipertensión portal no cirrotica. Reporte de caso. Rev Col Gastroenterol 2012: 27(4) 323-328.
7. Orozco-Delgado M, López-Cantero M, Zampe,la V, Vicente R, Galan J. Factores predicadores de mortalidad y estrategias de detección precoz de síndrome hepatopulmonar en pacientes transpalntados hepáticos. Rev Colombia Anestesiol 2106;44(4) 311-316.
8. Lyer VN, Swanson KI, Cartín CR, Dierkhising RA, Rasen CB, Hermbach JK, et.al. Hepatopulmonary syndrome: favorable outcomes ni the MELD exception Era. Hepatology jun 2013.57(6):2427-2435.
9. Carrillo ER, Gonzalez SJ, Serralde ZA. Síndrome Hepatopulmonar. Rev Fac Med 2001; 44:207-11.
10. Navasa M, Agusti C. Síndrome Hepatopulmonar. Asociación Española de Estudios del Higado. Avaible from: www.aeeh/org/tyrat enf hepaticac-17.pdf.
11. Lange PA, Stoller KJ. The Hepatopulmonary Syndrome. Ann Intern Med 1995;122: 521-28.
12. Grace JA, AngusPW. Hepatopulmonary syndrome: update on recent advances in phatophysiology, invetigation, and treatment. J Gastroenterol Hepatol 2013 Feb; 28(2), 213-9.
13. Rabiller A, Núñez H, Lebrec D, Tazl KA, Wartski M, Dulmet E, et. al. Prevention os gram-negative translocation reduces the severidad oh hepatopulmonary syndrome. Am J Respir Crit Care Med 2002; 66: 514-517.
14. Abad E, Amir AK, Seung KY. Pharmacologist treatment for hepatopulmonary syndrome. Brío Med Research International. 2013